Effect of iTBS on Children With ADHD

Exclusion Criteria

• •Concomitant mental disorders such as anxiety and depression;
• •Widespread developmental disorders and other neurological developmental related disorders;
• •Complication with other important organ diseases such as heart and lungs;
• •Suffering from diseases such as epilepsy and tic disorder;
• •Individuals who cannot tolerate rTMS treatment or cannot cooperate with treatment.
• •Patients taking psychoactive drugs, antipsychotics, antidepressants, or mood stabilizers 3 months prior to enrollment or during rTMS treatment; In addition to the minimum effective therapeutic dose of Tomoxetine (1.2-1.4 mg • kg/day), there has been systematic use of first-line ADHD drugs in clinical practice Webster's intelligence\<70
• •Implantation of metal and electronic components in the body (excluding the oral cavity), such as pacemakers;